These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection. Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP; Wu TS; Dan YY J Clin Pharm Ther; 2015 Aug; 40(4):368-75. PubMed ID: 25893507 [TBL] [Abstract][Full Text] [Related]
11. Review article: the clinical influence of Helicobacter pylori in effective acid suppression-implications for the treatment of gastro-oesophageal reflux disease. Martínek J; Kuzela L; Spicák J; Vavrecka A Aliment Pharmacol Ther; 2000 Aug; 14(8):979-90. PubMed ID: 10930891 [TBL] [Abstract][Full Text] [Related]
12. Gastroesophageal reflux disease and the relationship with Helicobacter pylori. Mungan Z; Pınarbaşı Şimşek B Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S61-S67. PubMed ID: 29199171 [TBL] [Abstract][Full Text] [Related]
13. Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease. Ghoshal UC; Blaachandran A; Rai S; Misra A Indian J Gastroenterol; 2022 Aug; 41(4):405-414. PubMed ID: 35771390 [TBL] [Abstract][Full Text] [Related]
14. Novel approaches to inhibition of gastric acid secretion. Sachs G; Shin JM; Hunt R Curr Gastroenterol Rep; 2010 Dec; 12(6):437-47. PubMed ID: 20924727 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers]. Choi YJ Korean J Gastroenterol; 2022 Dec; 80(6):247-253. PubMed ID: 36567437 [TBL] [Abstract][Full Text] [Related]
16. Predictors and timing for the development of symptomatic gastroesophageal reflux disease after successful Shinozaki S; Osawa H; Hayashi Y; Miura Y; Yano T; Lefor AK; Yamamoto H Scand J Gastroenterol; 2022 Jan; 57(1):16-21. PubMed ID: 34547219 [TBL] [Abstract][Full Text] [Related]
17. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636 [TBL] [Abstract][Full Text] [Related]
18. The use of proton pump inhibitors in children: a comprehensive review. Gibbons TE; Gold BD Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104 [TBL] [Abstract][Full Text] [Related]
20. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K Digestion; 2018; 97(3):212-218. PubMed ID: 29393194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]